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BACKGROUND Despite the high success rate of radiofrequency (RF) ablation, pharmacologic therapy is still
considered the standard initial therapeutic approach for atrial flutter.
OBJECTIVE We prospectively compared the outcome at follow-up of patients with atrial flutter randomly
assigned to drug therapy or RF ablation.
METHODS Patients with at least two episodes of symptomatic atrial flutter in the last four months were
randomized to regimens of either antiarrhythmic drug therapy or first-line RF ablation. After
institution of therapy, end points included recurrence of atrial flutter, rehospitalization and
quality of life.
RESULTS A total of 61 patients entered the study, 30 of whom were randomized to drug therapy and
31 to RF ablation. After a mean follow-up of 21 6 11 months, 11 of 30 (36%) patients
receiving drugs were in sinus rhythm, versus 25 of 31 (80%) patients who underwent RF
ablation (p , 0.01). Of the patients receiving drugs, 63% required one or more rehospital-
izations, whereas post-RF ablation, only 22% of patients were rehospitalized (p , 0.01).
Following RF ablation, 29% of patients developed atrial fibrillation which was seen in 53%
of patients receiving medications (p , 0.05). Sense of well being (pre-RF 2.0 6 0.3 vs.
post-RF 3.8 6 0.5, p , 0.01) and function in daily life (pre-RF 2.3 6 0.4 vs. post-RF 3.6 6
0.6, p , 0.01) improved after ablation, but did not change significantly in patients treated
with drugs.
CONCLUSION In a selected group of patients with atrial flutter, RF ablation could be considered a first-line
therapy due to the better success rate and impact on quality of life, the lower occurrence of
atrial fibrillation and the lower need for rehospitalization at follow-up. (J Am Coll Cardiol
2000;35:1898–904) © 2000 by the American College of Cardiology
In the past few years, several investigations have elucidated
the mechanism responsible for typical atrial flutter (1–6).
This appears to depend on a macroreentrant circuit that
includes, as a critical component, the right atrial tissue
surrounded by the tricuspid annulus, the inferior vena cava
and the coronary sinus with the eustachian valve and ridge.
This isthmus of atrial muscle appears as an ideal target for
ablation in view of the anatomic barriers and landmarks that
are easy to identify and localize. Creation of a complete line
of conduction block across either the tricuspid valve/
eustachian ridge isthmus (7) or the tricuspid valve/inferior
vena cava isthmus (8–15) has been shown to result in cure
of this arrhythmia. Despite the high success rate of radio-
frequency (RF) catheter ablation, however, pharmacologic
therapy is still considered the standard initial therapeutic
approach for atrial flutter. The objective of our study was to
assess and compare the clinical efficacy of conventional drug
therapy versus first-line catheter ablation to treat atrial
flutter in a prospective randomized study.
METHODS
This was a multicenter prospective randomized study. Con-
secutive patients referred to each institution were considered
eligible to enter the study if they had at least two symptom-
atic episodes of atrial flutter in the last four months.
Exclusion criteria included the following; 1) prior evidence
of atrial fibrillation (AF); 2) the presence of significant left
atrial enlargement ($4.5 cm); and 3) previous treatment
with antiarrhythmic medications. Electrocardioversion or
rate control therapy before entering the study was consid-
ered acceptable. Before entering the study, each patient
signed an informed and written consent. The study popu-
lation consisted of 61 patients. Of them, 42 were male and
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19 were female. Their mean age was 66 6 10 years and their
mean ejection fraction was 49 6 3%. After entering the
study, each patient was randomized to either pharmacologic
antiarrhythmic therapy or to first-line RF catheter ablation
of atrial flutter. Antiarrhythmic drugs were chosen by the
caring physician based on his or her preference. An effort
was made to keep each patient in the same treatment groups
for at least one year. Each investigator was required to
attempt sinus rhythm maintenance with at least two drugs,
including Amiodarone before resorting to rate control
medications. Recurrence of AF during Amiodarone therapy
was not considered a failure during the initial two months of
treatment with this drug.
Every patient enrolled in the study was given anticoagu-
lant therapy to maintain the international normalized ratio
between 2 and 3. Following enrollment in the study,
institution or change of antiarrhythmic therapy was per-
formed on an outpatient basis unless hospitalization was
required by the patient’s symptoms. Quality of life and
symptoms questionnaires were administered before institu-
tion of therapy, six and 12 months thereafter. The study end
points were as follows: 1) recurrence of atrial flutter (any
type of atrial flutter); 2) need for rehospitalization; and 3)
quality of life and symptom scales.
Electrophysiologic study and radiofrequency catheter
ablation. At the time of the study, all patients were sedated
with intravenous fentanyl and midazolam. Multipolar cath-
eters were placed in the coronary sinus, high right atrium
and His bundle recording position. In patients with sinus
rhythm at the time of the procedure, atrial flutter was
induced by programmed atrial stimulation. Isoproterenol
infusion was used when required for induction of atrial
flutter. Atrial flutter mapping and verification of the under-
lying mechanism were performed according to standard
criteria and techniques (4,5,12,16,17). Radiofrequency cur-
rent was delivered to the tip electrode of the ablation
catheter using either the EPT 1000 generator (EP Tech-
nology) or a Radionics RFG-3C generator (Radionics,
Inc.). Radiofrequency catheter ablation was performed by
creating linear lesion from the tricuspid annulus to the
inferior vena cava using 4- and/or 8-mm tip electrode
catheters advanced in the right atrium with a long 8F SRO
Daig sheath. The 8-mm tip catheter was used by the
investigators if with the 4-mm tip catheter adequate RF
energy delivery could not be achieved due to immediate
impedance rise even at low power setting. Radiofrequency
ablation was continued until either no electrogram or
consistent reduction of the electrograms amplitude of at
least 90% was documented across the isthmus. Even when
the continuity of the line of block was assessed and
confirmed by comparing the sequence of activation before
and after ablation during pacing from the coronary sinus,
and the lateral low right atrium, ablation was continued
until a uniformed reduction of the electrogram amplitude as
previously described was observed and persisted for 1 h of
observation. As part of the protocol, inducibility postabla-
tion was also assessed using extrastimulus testing and burst
pacing down to the shortest cycle length allowing 1:1
capture. Assessment of the continuity of the line of block
postablation was performed in 26 patients using either a
halo catheter (Cordis-Webster, Inc.) (11 patients) or by
placing a custom-made catheter for recording, pacing and
defibrillation which consisted of eight distal electrodes
advanced in the coronary sinus and eight proximal elec-
trodes separated by a 9-cm gap (15 patients). The eight
proximal electrodes were positioned along the mid-high
posterolateral region of the right atrium anterior to the
crista terminalis. In these 15 patients, the eight distal
electrodes served as coronary sinus recording pairs. In the
last three patients undergoing ablation in this study, bidi-
rectional block across the isthmus was assessed using a
nonfluoroscopic mapping system (Carto-Biosense, Inc.).
Even in those cases, ablation was continued until electro-
gram amplitude reduction was achieved across the isthmus.
Quality of life and symptoms in activity scale question-
naire. An assessment of the patients quality of life before
and after the procedure was performed using a questionnaire
that included 16 items to evaluate the physical, social,
economics and psychological impairment (Endicott, Qual-
ity of Life Enjoyment and Satisfaction Questionnaire) (18).
Each item was scored on a scale from 1 to 5 from very poor
to very good. Each patient was also asked to score selected
symptoms on a scale from 1-absent, to 4-extremely severe or
from 1-never, to 5-always. Quality of life and symptoms
scores were obtained before the procedure, and six and 12
months after entering this study.
Follow-up. All patients undergoing catheter ablation had
treatment with the medications used for rate control dis-
continued. All patients were followed up in the outpatient
clinic at regular intervals. Patients were seen in the outpa-
tient clinic at one, three, six and 12 months after the
ablation procedures or after initiation of antiarrhythmic
therapy. In addition, patients were advised to reach their
electrophysiologist if any symptoms of palpitation or irreg-
ular heart beat occurred after institution of therapy or the
ablation procedure. In case of recurrence of atrial flutter
after ablation, the procedure was repeated. In case of
recurrence of atrial flutter in patients treated with antiar-
rhythmic therapy, a different antiarrhythmic drug was ini-
tiated on an outpatient basis unless the patient required
hospitalization because of severe symptoms. If patients
experienced AF after entering the study, the arrhythmia was
treated with medical therapy based on the preference of the
Abbreviations and Acronyms
AF 5 atrial fibrillation
AV 5 atrioventricular
RF 5 radiofrequency
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caring electrophysiologist. The investigators were required
to monitor patients by Holter or loop recordings at least at
one, three and six months and in the presence of any
symptoms of rapid or irregular heart beat.
Statistical analysis. Quality of life and activities scores
were analyzed with the use of one-way analysis of variance
to discern changes over time within the groups. Comparison
between continuous variables was obtained by paired and
unpaired Student’s t test, as appropriate. Comparison be-
tween proportions was performed by the Fisher’s exact test.
A p value ,0.05 was considered statistically significant.
RESULTS
Patient population. A total of 61 patients were enrolled in
this study. Of them, 42 were male and 19 were female. The
clinical characteristics between the two groups were not
different. The mean age, gender distribution, mean ejection
fraction, presence or absence of structural heart disease,
frequency and type of arrhythmia before and after entry in
the study are shown in Table 1.
Result of the catheter ablation procedure. Acute success-
ful ablation was obtained in all 31 patients undergoing RF
catheter ablation. In all patients, the ablation was initiated
with a 4-mm tip electrode and concluded with an 8-mm tip
electrode in five of them. Twenty-six of 31 patients had only
isthmus-dependent atrial flutter. In the remaining five
patients, an incisional atypical atrial flutter was induced or
documented either as the only arrhythmia (in three patients)
or in association with an isthmus-dependent flutter (in two
patients). Of the incisional flutter, four were associated with
a posterolateral scar from which a linear lesion was extended
down to the inferior vena cava. In one patient with inci-
sional flutter, the scar was identified in the septum and a
lesion was made extending from the scar up to the superior
vena cava and down to the eustachian valve.
Among the 26 patients undergoing verification of bidi-
rectional block along the ablation line we observed the
following: 1) that bidirectional block was present immedi-
ately following termination of atrial flutter by catheter
ablation in 11 patients (42%); 2) that after demonstration of
bidirectional block, additional lesions were required in four
patients (15%) to satisfy the electrogram amplitude end
Table 1. Baseline Characteristics of the Two Patient Groups
RF Ablation
(n 5 31)
Drug Therapy
(n 5 30)
p
Value
Age (yr) 67 6 8 66 6 11 NS
Male gender 20 22 NS
Mean EF (%) 49.4 6 5.1 49.6 6 3.1 NS
Structural heart disease:
Absent 16 17
IHD 12 11
IDC 2 1
VD 1 —
Other — 1
Paroxysmal atrial flutter (n) 1 2 NS
Persistent atrial flutter (n) 30 28 NS
Median episodes per month of
atrial flutter (range)
1 (0–3) 1 (0–2) NS
Mean No. of cardioversions
before entering the study
2.3 6 0.5 2.2 6 0.5 NS
Mean No. of cardioversions
after entering the study
0.5 6 1.2 4.4 6 1.7 , 0.01
Percentage of patients with
atrial flutter recurrence
after entering the study
6% (2) 93% (28) , 0.01
Percentage of patients with
atrial fibrillation after
entering the study
29% (9) 60% (18) , 0.05
Mean No. of arrhythmia
episodes at follow-up
0.7 6 1.4 5.1 6 2.0 , 0.01
Percentage of patients requiring
arrhythmia-related
hospitalization at follow-up
22% (7) 63% (19) , 0.01
EF 5 ejection fraction; IDC 5 idiopathic dilated cardiomyopathy; IHD 5 ischemic heart disease; RF 5 radiofrequency; VD 5
valvular disease.
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point; and 3) that uniform reduction of the electrogram
amplitude across the isthmus was never associated with
persistence of conduction throughout this region.
There was no occurrence of atrioventricular (AV) block
or pericardial effusion in the ablation group. One patient
experienced chest discomfort, that persisted for about two
weeks after the procedure. Another patient had hematoma
at the site of the venous puncture which, however, did not
require any transfusion or specific intervention. At the end
of the one-year follow-up considered for this study, two
patients experienced recurrence of atrial flutter (6.4%) and
they were both treated with repeat ablation. Nine patients
experienced AF after successful catheter ablation of atrial
flutter (29%). Of these nine patients, five were treated with
antiarrhythmic drugs with long-term persistence of normal
sinus rhythm. Three patients had sporadic episodes of
self-terminating AF and were treated with rate-control
drugs including diltiazem in two patients and metoprolol in
one patient. One patient did not respond to antiarrhythmic
drugs and because rate control was difficult to achieve with
medication, he underwent AV node ablation and implan-
tation of a single-chamber permanent pacemaker nine
months after the initial ablation for atrial flutter.
Drug therapy group. The mean number of drugs initiated
in this group of patients was 3.4 6 1.1. The type of drugs
administered in individual patients is shown in Table 2. At
follow-up, 16 (53%) of these patients were treated with rate
control drugs due to the inefficacy of active antiarrhythmics
in maintenance of sinus rhythm. Of these 16 patients, 15
had both recurrence of atrial flutter and development of AF.
The remaining patient had occurrence of AF that did not
respond to medical management. At the time of the first
arrhythmia recurrence, AF was observed in one patient,
whereas all the remaining patients had atrial flutter. Two
patients crossed over to atrial flutter ablation before the end
of the first year of follow-up and one patient required AV
node ablation and pacemaker due to the inability to main-
tain normal sinus rhythm and to achieve adequate rate
control. In this patient, both atrial flutter and AF were
observed. Of the remaining 11 patients, 8 were treated with
amiodarone, 1 with propafenone and atenolol, and 2 with
procainamide and digoxin. Of the 16 patients receiving rate
Table 2. Medications Administered in the Drug Therapy Group After Enrollment
Patient No. Drug 1 Drug 2 Drug 3 Drug 4 Final Therapy
1 Sotal Prop 1 Ver Amio Amio
2 Flecain 1 Aten Sotal Amio Aten Aten
3 Dig 1 Prop Amio Amio
4 Sotal Prop 1 Ver Amio Ver 1 Dig Ver 1 Dig
5 Prop 1 Aten Prop 1 Aten
6 Flecain 1 Dig Procain 1 Dig Sotal Amio Amio
7 Procain 1 Dig Prop 1 Dig Amio Ver 1 Dig Ver 1 Dig
8 Sotal Amio Amio
9 Flecain 1 Aten Sotal Amio Aten 1 Dig Aten 1 Dig
10 Flecain 1 Dig Procain 1 Dig Procain 1 Dig
11 Procain 1 Dig Flecain 1 Dig Sotal Amio RF Abl
12 Amio Quinid 1 Dig Prop 1 Aten Aten 1 Dig Aten 1 Dig
13 Procain 1 Dig Prop 1 Aten Amio Dilt 1 Dig Dilt 1 Dig
14 Sotal Prop 1 Ver Amio Metop Metop
15 Sotal Amio Dilt 1 Dig Dilt 1 Dig
16 Procain 1 Dig Prop 1 Dig Sotal Amio AV node Abl 1 PPM
17 Sotal Flecain 1 Aten Amio Ver 1 Dig Ver 1 Dig
18 Prop 1 Dig Sotal Flecain 1 Aten Amio Amio
19 Flecain 1 Aten Sotal Amio Procain 1 Dig Aten 1 Dig
20 Sotal Prop 1 Dig Amio Ver 1 Dig Ver 1 Dig
21 Sotal Prop 1 Dig Amio Dig Dig
22 Amio Sotal Prop 1 Aten RF Abl
23 Procain 1 Dig Procain 1 Dig
24 Amio Sotal Prop 1 Dig Metop Metop
25 Sotal Prop 1 Aten Procain 1 Dig Amio Amio
26 Quinid 1 Dig Prop 1 Ver Amio Aten Aten
27 Flecain 1 Dig Sotal Amio Dilt 1 Dig Dilt 1 Dig
28 Sotal Prop 1 Aten Amio Amio
29 Amio Prop 1 Aten Sotal Dig Dig
30 Amio Amio
Amio 5 amiodarone; Aten 5 atenolol; AV 5 atrioventricular; Dig 5 digoxin; Dilt 5 diltiazem; Flecain 5 flecainide; Metop 5 metoprolol; PPM 5 permanent pacemaker
following AV node ablation; Procain 5 procainamide; Prop 5 propafenone; Quinid 5 quinidine; RF Abl 5 catheter ablation of atrial flutter; Sotal 5 sotalol; Ver 5 verapamil.
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control drugs, 2 were treated with digoxin alone, 7 with
diltiazem or verapamil combined with digoxin, 4 with
beta-adrenergic blocking agents alone and 3 with a combi-
nation of beta-blocker and digoxin.
Quality of life and symptoms for assessment. The scores
of the overall sense of well being and the most relevant
symptoms before and after institution of drug therapy or
catheter ablation are shown in Tables 3 and 4. In the
patients randomized to drug therapy, with the exception of
palpitation, there was no statistically significant change in
all the variables presented. Differently, the patients treated
with catheter ablation reported a significant improvement in
their quality of life and symptoms scores.
Follow-up results. Besides the overall success rate and
crossover previously mentioned, after a mean follow-up of
22 6 11 months, 25 patients (80%) who underwent catheter
ablation were in sinus rhythm without the need of active
antiarrhythmic drugs, whereas only 11 (36%, p , 0.01) of
those receiving antiarrhythmic therapy remained in sinus
rhythm. At follow-up, AF was seen in 9 patients undergo-
ing catheter ablation (29%) versus 18 of those receiving
antiarrhythmic drug therapy (60%, p , 0.05). Eight of the
nine patients (88%) experiencing AF following catheter
ablation had this arrhythmia controlled by medical therapy.
Differently, in the drug therapy group, only 1 of the 18
patients (6%) developing AF had this arrhythmia success-
fully managed with drugs.
During the follow-up period, hospitalization was re-
quired for occurrence of severely symptomatic arrhythmia in
7 patients (22%) undergoing catheter ablation and 19 (63%,
p , 0.01) of those receiving medication. Among the
patients treated with antiarrhythmic drugs, recurrence of
atrial flutter was never associated with 1:1 AV conduction.
At follow-up, the median number of Holter or loop moni-
torings was 5 (ranged from 3 to 10) in the drug therapy
group and 3 (ranged from 3 to 7) in the ablation group.
DISCUSSION
Radiofrequency catheter ablation has revolutionized treat-
ment for patients with supraventricular tachycardia involv-
ing either AV node reentry or AV reentry as the underlying
mechanism. For these patients, catheter ablation has been
proved to be a curative therapy with low rate of complica-
tions and may also represent a cost-effective approach as
compared with a life-long medical treatment. However, for
patients with atrial flutter, catheter ablation is considered an
option only after drug therapy has failed. Although large
prospective series assessing the efficacy of drug therapy only
for atrial flutter are lacking in the literature, in general, is
recognized that medical management of this atrial arrhyth-
mia can be particularly difficult and may cause a higher risk
of morbidity and mortality secondary to bradyproarrhyth-
mia or tachyproarrhythmia. This is certainly more common
in patients with associated heart disease, which is more
frequently encountered in subjects with atrial flutter.
Table 3. Quality of Life and Symptoms Scores in the Drug Therapy Group
Pretreatment
Posttreatment
(6 mo)
Posttreatment
(12 mo)
Overall
p Value
Sense of well being 1.9 6 0.4 2.0 6 0.4 2.1 6 0.3 NS
Function in daily life 2.1 6 0.4 2.1 6 0.3 2.3 6 0.3 NS
Palpitation 3.2 6 0.6* 2.0 6 0.5 2.1 6 0.7 , 0.05
SOB with exercise 3.4 6 0.4 3.2 6 0.4 3.0 6 0.5 NS
Feeling weak 2.9 6 0.3 3.0 6 0.4 3.1 6 0.4 NS
QOL total score 29 6 3 28 6 6 31 6 5 NS
*p , 0.001. Pretreatment versus posttreatment 6 months and posttreatment 12 months. All other comparisons did not show
statistical significance.
QOL 5 quality of life overall score; SOB 5 shortness of breath.
Table 4. Quality of Life and Symptoms Scores in the Catheter Ablation Group
Preablation
Postablation
(6 mo)
Postablation
(12 mo)
Overall
p Value
Sense of well being 2.0 6 0.3* 3.9 6 0.3 3.8 6 0.5 , 0.01
Function in daily life 2.3 6 0.4* 3.8 6 0.5 3.6 6 0.6 , 0.01
Palpitation 3.1 6 0.6* 1.0 6 0.4 1.0 6 0.5 , 0.01
SOB with exercise 3.0 6 0.4* 1.0 6 0.5 1.2 6 0.3 , 0.01
Feeling weak 2.9 6 0.5* 0.8 6 0.4 0.8 6 0.5 , 0.01
QOL total score 30 6 4† 59 6 7 57 6 6 , 0.001
*p , 0.001. Preablation versus postablation 6 months and postablation 12 months. †p , 0.0001. Preablation versus postablation
6 months and postablation 12 months. Postablation 6 months versus postablation 12 months, p 5 NS.
QOL 5 quality of life overall score; SOB 5 shortness of breath.
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Background. In the past few years, our understanding of
the electrophysiologic and anatomic substrate of atrial
flutter has grown considerably and has led to the implemen-
tation of effective ablative therapies (1–17). Once corridors
of slow conduction are identified, either in the isthmus
between the tricuspid annulus and the eustachian ridge or
between a surgical scar and other right atrial anatomic
boundaries, creation of linear lesions by RF catheter abla-
tion has been proved to be effective and safe (7–17). It is
therefore reasonable to consider this approach an alternative
to standard medical therapy. However, prospective studies
are lacking to support early catheter ablation for the treat-
ment of atrial flutter.
Study findings. The present investigation provides data
that justified catheter ablation of atrial flutter as a first-line
approach as compared with active antiarrhythmic medica-
tions. In our series, atrial flutter ablation was not only more
effective in the long-term management of this arrhythmia,
but also required less rehospitalizations; it was also associ-
ated with lower occurrence of atrial fibrillation during the
follow-up.
It is also important to recognize that most patients
treated with antiarrhythmic therapy did not perceive their
quality of life and symptoms positively impacted by this
intervention. However, catheter ablation by providing a cure
for more patients was associated with a significant improve-
ment of all the variables assessed.
Technical issues. Interestingly, the recurrence rate ob-
served in our series is either lower or similar than what was
previously reported (1,7,9,13–17). This could reflect our
ablation approach, which was targeted to eliminate electro-
grams in the isthmus region by performing ablation with an
8-mm tip electrode in nearly all the patients. However,
procedures in which the continuity of the line of block was
assessed by demonstration of complete bidirectional con-
duction block across the right atrial isthmus following the
procedure were associated with a recurrence rate similar to
our series (3,10,11,19,20). It is possible that our extensive
ablation may have resulted in a higher likelihood of achiev-
ing continuous and persistent bidirectional block. However,
in a preliminary report by Tomassoni et al. (21), continuous
and bidirectional conduction block across linear lesions with
intentional gaps has been demonstrated in the acute setting
by high density electrical mapping. Similarly, Tomassoni et
al. (21) and other investigators (22) observed that the best
predictor of contiguous and transmural lesions was the
attenuation of the electrogram amplitude. This may argue
against more limited ablation procedures and may explain
the overall good success rate achieved in our series despite
sophisticated techniques to assess complete bidirectional
block after ablations were not performed consistently.
Clinical implications. Several studies have reported a sig-
nificant occurrence of AF after ablation of type I atrial
flutter (14,19,23–25). Although clinical characteristics were
recognized as predictors of the occurrence of this arrhythmia
after catheter ablation, the frequency of onset of AF
following the procedure raised concerns about the potential
proarrhythmic effect of the procedure itself. Our study,
while confirming the occurrence of AF in a significant
number of patients following ablation, appeared to exclude
proarrhythmic effects of this procedure. In fact, atrial
fibrillation occurred more frequently in the group of patients
treated with antiarrhythmic therapy. This finding has two
important implications: 1) in some of these patients, AF
may reflect the existence of an altered electrical substrate
that is not the result of the ablation procedure and does not
reflect the delayed effect of discontinuation of suppressive
antiarrhythmic therapy previously used; and 2) the ineffec-
tive prevention of atrial flutter by antiarrhythmic therapy
may potentiate an unfavorable electrical remodeling of the
atrium which, in turn, could facilitate degeneration to AF at
follow-up, as demonstrated in our series. Considering the
significant morbidity and mortality associated with the
presence of AF, this observation represents an additional
argument to support catheter ablation as a first-line ap-
proach in the treatment of atrial flutter.
Finally, although our series is not sufficiently powered to
provide strong statistical evidence, AF after catheter abla-
tion of atrial flutter appeared easier to control with medical
management.
In our study, initiation or change of medical therapy was
performed on an outpatient basis. Despite this practice,
hospitalization was required due to significant symptoms
associated with recurrence of tachyarrhythmias in a larger
proportion of patients treated with antiarrhythmic therapy.
Therefore, it is possible that antiarrhythmics also have the
potential to increase the overall cost of this treatment
approach. In addition, one must consider that most of our
patients were ultimately treated with amiodarone which,
over time, may be associated with a significant incidence of
side effects; this was not observed in our series probably due
to the short study follow-up. This certainly represents a
concern that must be weighed when proposing treatment
options to patients with atrial flutter.
CONCLUSION
In this prospective randomized study, catheter ablation of
atrial flutter in a selected group of patients with normal or
mildly enlarged left atrial size appeared to be associated with
a higher likelihood of persistence of sinus rhythm, a signif-
icant improvement of quality of life and symptoms scores, a
lower occurrence of AF and less need for rehospitalization at
follow-up. In view of the low efficacy and the higher
persistence of atrial flutter and AF observed with conven-
tional medical management, catheter ablation could be
considered a first-line therapy for atrial flutter, at least in
patients with clinical characteristics similar to those of the
subjects entered in this study. Whether our findings can be
extended to the overall patient population with atrial flutter
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is likely, but it requires further investigations. In addition,
this study was designed to assess the efficacy of catheter
ablation versus antiarrhythmic therapy in preventing reoc-
currence of atrial flutter. Whether maintenance of sinus
rhythm has any impact on mortality as compared with rate
control therapy is not clear at this point.
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